直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

The New Director Institution Process: USPTO Hour Webinar Provides Updates and First Decision is Released

November 4, 2025

Authored and Edited by Christine M. Akagi; Umber Aggarwal; Forrest A. Jones

On October 29, 2025, the USPTO held a USPTO Hour to discuss Director institution for AIA trial proceedings following the October 17, 2025, memorandum (“Director Institution Memorandum”) by Director Squires, which was discussed in a previous post. As previously discussed, the Director Institution Memorandum revoked the delegation of institution decisions from panels of Administrative Patent Judges (APJs) at the Board. Instead, the Director will issue decisions granting or denying institution. And on Friday, October 31, 2025, we received the first decision, denying 13 unrelated IPRs in one document.

Acting Chief Judge Kalyan Deshpande and Vice Chief Judge Michael Kim led the discussion and presentation of accompanying slides.

Key Takeaways

  1. The Director, in consultation with at least three APJs, will decide whether to institute all inter partes review (IPR) and post-grant review (PGR) petitions. For some complex cases, the Director may refer the decision to a panel of one or more PTAB judges.
  2. The Director will not provide analysis when issuing summary notices either instituting or denying a petition. This was confirmed by the Director’s first set of institution decisions, a single summary notice denying thirteen IPR proceedings with no stated reasoning. The Director may still issue decisions with reasoning at his discretion for important issues.
  3. The Director Institution Memorandum became effective on October 20, 2025, and applies to all petitions that had not been referred to a PTAB panel by that date.
  4. The Director Institution Memorandum does not change the conduct of AIA trials.

Process Overview

Under the new institution procedures, the Director, in consultation with at least three APJs, will determine whether to institute all IPR or PGR trials. The three APJ panel will typically not be the same APJs on the trial panel, and the panel identities are unlikely to be disclosed consistent with the interim bifurcated review process.

Decisions will be based on review of the merits, discretionary considerations, and non-discretionary factors. There are three types of institution decisions under these procedures: summary notices, full decisions, and referral decisions. Notably, petitions for ex parte reexamination (EPR) are not subject to the new Director procedures.

Summary Notices: These will only state the outcome of the decision (i.e., institution or denial) and will not specify why, including whether a denial is merit-based or discretionary. Most decisions will be issued as summary notices.

Full Decisions: The Director may provide full decisions when the proceeding involves an important issue, such as novel or significant factual or legal questions.

Referral Decisions: These decisions will be referred by the Director to one or more PTAB members (e.g., APJs) when a more detailed analysis is needed. This may occur in cases involving complex claim construction, complicated priority questions, or disputes about real parties in interest.

Post-Institution Process

Once instituted, IPR and PGR proceedings will be referred to a three-member APJ panel for trial as per usual. Panels will be assigned according to PTAB Standard Operating Procedure (SOP) 1 (Rev. 16). Scheduling orders will not be issued with the institution decision but will be determined by the assigned panel as the case progresses. The Director has not made any other changes to the conduct of AIA trials at this time.

Procedural Details

Party briefings, including bifurcated discretionary denial briefing, and due dates remain unchanged. Before institution, motion requests and other questions should be emailed to Director_DI@uspto.gov. After institution, these communications should be emailed to trials@uspto.gov.

Petitions referred to the three-member APJ panel before October 20, 2025 will follow the previous process of being reviewed by a three-member panel. This includes referrals made under the discretionary denial process and referrals made after the patent owner has failed to file a discretionary denial brief. In these instances, the APJ panel will decide whether the petition merits warrant institution.

Decision Timing

The Office released the first decisions under the new procedures on October 31, 2025, all of which were denials. Notably, the first decisions were released as a singular notice merely listing the thirteen denied petitions without any accompanying explanation.

The Office indicated that most decisions released through November would also be denials, anticipating that institutions would begin to issue once a steady state is reached. Decisions are expected to be released weekly, likely on Fridays.

While there is currently no set decision timeline, the Office has committed not to “sit on decisions” and to act before the existing six-month deadline. The Office claimed that each petition will be reviewed thoroughly, stating that the Director “will take as much time as it takes.” The Office has not yet specified where decisions will be posted, aside from the Patent Trial and Appeal Case Tracking System (P-TACTS).

Review and Appeals

Parties may request rehearing or Director review of summary notices. The standard for review remains unchanged: institution decisions may be challenged only on the grounds of (a) an abuse of discretion, (b) important issues of law or policy, (c) erroneous findings of material fact, or (d) erroneous conclusions of law. However, because summary notices are issued without any reasoning, it remains unclear how parties can effectively argue these grounds, particularly erroneous findings of fact or conclusions of law, when the decision provides neither factual findings nor legal conclusions.

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Offices

Washington, DC

Contacts

Christine M. Akagi
Law Clerk
Washington, DC
+1 202 408 4478
Email
Umber Aggarwal
Associate
Reston, VA
+1 571 203 2423
Email
Forrest A. Jones
Partner
Washington, DC
+1 202 408 4019
Email

Copyright © 2025 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Lecture

Munich Licensing Summer Course 2026

June 18-19, 2026

Munich

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Conference

Best Practices and Tech in Intellectual Property Conference 2026

May 17, 2026

Tel Aviv

Articles

COPPA’s Amended Rule Is Now in Full Effect: What Operators Need to Know

May 15, 2026

Seminar

IP Strategy at the Crossroads: Technology, Enforcement, and Contracts

May 15, 2026

Taipei

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP